

United States Patent and Trademark Office

CNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virgnia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/730,627	12/08/2003	Brian D. Halevie-Goldman	306822 15566	4270
7590 02/10/2005			EXAM	INER
PILLSBURY WINTHROP LLP Suite 2800			RUSSEL, JEFFREY E	
725 South Figueroa Street			ART UNIT	PAPER NUMBER
Los Angeles, CA 90017-5406			1654	

DATE MAILED: 02/10/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

			*		
	Application No.	Applicant(s)			
Office Action Summer	10/730,627	HALEVIE-GOLDMAN, BRIAN D.			
Office Action Summary	Examiner	Art Unit			
	Jeffrey E. Russel	1654			
The MAILING DATE of this communication apportunity Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period with Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	6(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	nely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 15 Ja	nuary 2004.				
	action is non-final.				
3) Since this application is in condition for allowan closed in accordance with the practice under Ex	ce except for formal matters, pro				
Disposition of Claims					
4) Claim(s) 1-45 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-45 are subject to restriction and/or e	n from consideration.	·			
Application Papers					
9)☐ The specification is objected to by the Examiner	•				
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the d	lrawing(s) be held in abeyance. See	37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Exa					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a a All b Some * c None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priori application from the International Bureau * See the attached detailed Office action for a list of	have been received. have been received in Application ty documents have been received (PCT Rule 17.2(a)).	on No d in this National Stage			
Attachment(s)					
) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413)			
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail Da				

Application/Control Number: 10/730,627

Art Unit: 1654

This application contains claims directed to the following patentably distinct species of 1. the claimed invention: The species of opiate destruction-inhibitors which are hydrocinnamic acid, D-PA, thiolbenzyl-phenylalanine, a dipeptide of essential amino acids in D-form, a tripeptide of essential amino acids in D-form, an enkephalin fragment, a dipeptide comprising tyrosine, a dipeptide comprising L-leucine, an oligopeptide or polypeptide comprising D-Phe-D-Leu, an oligopeptide or polypeptide comprising D-Phe-D-Met, and DLPA, are patentably distinct from one another because of their materially different structures. The species of neurotransmitter precursors which are L-Phe, L-dopa, L-Tyr, 5-hydroxytryptophan, L-Trp, L-Glutamine, and Lglutamic acid/L-glutamate are patentably distinct from one another because of their materially different structures. The species of cofactors which are N-acetyl-tyrosine, coleus forskohlii, Lglutamine, mucuna pruriens, rhodiola rosea, pregnenalone, chromium picolinate, chromium polynicotinate, L-Methionine, methylcobalamin-vitamin B12, betaine-TMG, 7-oxo-DHA, acetyl-l-carnitene, green tea catechins, and L-theanine are patentably distinct from one another because of their materially different structures. For each group of compounds, a search for one species will not satisfy the search requirements for the other species.

Page 2

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species of opiate destruction-inhibitor, a single disclosed species of neurotransmitter precursor, and a single disclosed species of cofactor for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-45 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable

Art Unit: 1654

thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

- 2. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey E. Russel at telephone number (571) 272-0969. The examiner can normally be reached on Monday-Thursday from 8:30 A.M. to 6:00 P.M. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor Bruce Campell can be reached at (571) 272-0974. The fax number for formal communications to be entered into the record is (571) 273-8300; for informal communications such as proposed amendments, the fax number (571) 273-0969 can be used. The telephone number for the Technology Center 1600 receptionist is (571) 272-1600.

Jeffrey E. Russel

Primary Patent Examiner

Art Unit 1654

JRussel

February 8, 2005